KMPH
Zevra Therapeutics Inc
$5.81
Earnings Summary
Revenue | $2.87Mn |
Net Profits | $-6.62Mn |
Net Profit Margins | -230.2% |
Highlights
Zevra Therapeutics Inc’s revenue jumped 46.26% since last year same period to $2.87Mn in the Q3 2022. On a quarterly growth basis, Zevra Therapeutics Inc has generated 121.08% jump in its revenue since last 3-months.
Zevra Therapeutics Inc’s net profit fell -276.12% since last year same period to $-6.62Mn in the Q3 2022. On a quarterly growth basis, Zevra Therapeutics Inc has generated 72.48% jump in its net profits since last 3-months.
Zevra Therapeutics Inc’s net profit margin fell -157.16% since last year same period to -230.2% in the Q3 2022. On a quarterly growth basis, Zevra Therapeutics Inc has generated 87.55% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Zevra Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Current Year | -0.17 |
Highlights
Zevra Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a -30.77% fall from last quarter’s estimates.
Zevra Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.17.
Key Ratios
Key ratios of the Zevra Therapeutics Inc post its Q3 2022 earnings
Earning Per Share (EPS) | -0.19 |
Highlights
Zevra Therapeutics Inc’s earning per share (EPS) fell -280% since last year same period to -0.19 in the Q3 2022. This indicates that the Zevra Therapeutics Inc has generated -280% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-11-10 | -0.13 | -0.19 | -46.15% |
2022-08-12 | -0.12 | -0.7 | -483.33% |
2022-05-12 | -0.05 | -0.05 | 0% |
₹0 US Stocks a/c Opening Fee